Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2020 | Managing ALK+ NSCLC

Stephen Liu • 30 Jan 2020
BTOG 2020
Lung Cancer Non-Small Cell Lung Cancer Alectinib Brigatinib Crizotinib
ALTA-1L

Stephen Liu, MD, MedStar Georgetown University Hospital, Washington, DC, outlines how will frontline ALK+ non-small cell lung cancer (NSCLC) be managed, highlighting the management of brain metastases This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

More from Stephen Liu

2:09
ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC
Stephen Liu • 30 Jan 2020
1:30
A shifting paradigm: lung cancer
Stephen Liu • 30 Jan 2020
1:48
Stephen Liu: BTOG highlights
Stephen Liu • 30 Jan 2020
5:08
Actionable lung cancer targets
Stephen Liu • 30 Jan 2020

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals